絞り込み

17791

広告

Triptolide improves spinal cord injury by promoting autophagy and inhibiting apoptosis.

著者 Zhu N , Ruan J , Yang X , Huang Y , Jiang Y , Wang Y , Cai D , Geng Y , Fang M
Cell Biol Int.2019 Nov 27 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (18view , 0users)

Full Text Sources

Miscellaneous

Research Materials

We investigated the effect of triptolide (TP) on spinal cord injury (SCI), and its underlying mechanism. Following the establishment of the SCI model using YFP H-line transgenic mice, TP was intraperitoneally injected at a dose of 0.2 mg/kg once daily for 7 days. Behavioral tests, Nissl staining and HE staining were employed to assess motor function recovery and neuronal cell death. Western blot and immunofluorescence staining were used to assess autophagy-associated proteins (LC3B, p62, Beclin-1), and the apoptotic-associated proteins (Bcl-2, caspase-3, Bax). TP-treated group showed improved motor functions, and reduced neuronal cell death. Also, significant upregulation of Bcl-2 and LC3B expressions, with the downregulation of p62, Bax and caspase-3 expressions were found in TP-treated group. Additionally, phosphorylation of extracellular signal-regulated protein kinases 1 and 2 (ERK1 and ERK2) was decreased in the TP-treated group. TP mediate its protective effect in SCI by promoting the autophagic pathway while inhibiting the MAPK/ERK1/2 signaling pathway. These results demonstrate the therapeutic potential of TP in SCI. This article is protected by copyright. All rights reserved.
PMID: 31774600 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード